《新股》银诺医药(02591.HK)传超购5,364倍 料成今年超购王第二位

阿斯达克财经
Aug 13

港交所(00388.HK) 本月初修订首次公开发售(IPO)市场定价及公开市场规定,优化新股回拨机制,首只在新制实施后招股的新股银诺医药(02591.HK)昨日(12日)截止招股,根据市场消息,银诺医药公开发售部分超额认购约5,364倍,有约26万人认购,涉资约3,700亿元,预料超越超购5,257倍的蜜雪集团(02097.HK) ,成为今年新股超购王第二位,仅次于超购近6,000倍的布鲁可(00325.HK) 。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-12 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10